Matthew K. Szot
Matthew K. Szot's purchase track record
Matthew K. Szot has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/1/2022 | IVF | $14K | +6.4% | +7.6% | -0.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
SNES Included in 12 Health Care Stocks Moving in Pre‑Market Session. SenesTech Inc. (SNES) was listed among 12 health‑care names that saw movement in Tuesday’s pre‑market session. The stock experienced a volume spike and is trading near its $1.59 support level, below its 52‑week range. Analysts have a target range of $3.50 to $10.00, with an average of $6.75. The move reflects short‑term interest rather than a fundamental shift.
Transaction History
| CVKD | ▼ Sell | Open Market | 9,933 | $69K | 12/29/2025 | View on chart |
| IVF | ▼ Sell | Other | 3 | $0 | 12/4/2025 | View on chart |
| IVF | ▼ Sell | Open Market | 4 | $6 | 12/3/2025 | View on chart |
| SNES | ▼ Sell | Open Market | 1 | $3 | 11/14/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 1,800 | $25K | 10/27/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 1,800 | $25K | 10/24/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 1,800 | $25K | 10/13/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 1,693 | $24K | 10/9/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 107 | $1K | 10/6/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 1,700 | $24K | 10/1/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 100 | $1K | 9/29/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 10,900 | $153K | 9/25/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 1,500 | $21K | 9/24/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 400 | $6K | 8/28/2025 | View on chart |
| CVKD | ▼ Sell | Open Market | 1,600 | $22K | 8/27/2025 | View on chart |
| CVKD | ▲ Buy | Grant | 50,000 | $0 | 1/24/2023 | View on chart |
| IVF | ▲ Buy | Open Market | 14,474 | $14K | 6/1/2022 | View on chart |
| IVF | ▲ Buy | Grant | 10,250 | $0 | 1/15/2022 | View on chart |
| IVF | ▲ Buy | Grant | 12,112 | $0 | 12/31/2020 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Cadrenal hires Tungsten Advisors to drive strategic process
Cadrenal Therapeutics has appointed Tungsten Advisors to lead a formal strategic process aimed at maximizing the value of its orphan thrombo‑inflammatory drug portfolio. The move signals a focus on unlocking potential upside for the company’s niche therapeutics. Investors may view this as an effort to improve the company’s valuation prospects. The stock remains near its 12‑touch support level at $1.05.
Cadrenal hires Tungsten Advisors to drive strategic process. Cadrenal Therapeutics has appointed Tungsten Advisors to lead a formal strategic process aimed at maximizing the value of its orphan thrombo‑inflammatory drug portfolio. The move signals a focus on unlocking potential upside for the company’s niche therapeutics. Investors may view this as an effort to improve the company’s valuation prospects. The stock remains near its 12‑touch support level at $1.05.